Inflammation and extracellular matrix protein metabolism: Two sides of myocardial remodelling

European Heart Journal, Supplement

Volumn 4, Issue I, 2002, Pages

  Pauschinger, M ^a   Chandrasekharan, K ^a   Li, J ^a   Poller, W ^a   Noutsias, M ^a   Tschope, C ^a   Schultheiss, H P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokines; Extracellular matrix; Matrix metalloproteinases; Myocarditis

Indexed keywords

COLLAGEN; CYTOKINE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

AUTOCRINE EFFECT; CELL INTERACTION; COLLAGEN SYNTHESIS; CONFERENCE PAPER; EXTRACELLULAR MATRIX; HEART DILATATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOCOMPETENT CELL; INFLAMMATION; INTERSTITIUM; MYOCARDITIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS REGULATION;

EID: 0036899387     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90111-2     Document Type: Conference Paper

References (48)

1. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-92.
2. Weber KT, Sun Y, Katwa LC, Cleutjens JP. Connective tissue: A metabolic entity? J Mol Cell Cardiol 1995; 27: 107-20.
3. Pauschinger M, Doerner A, Remppis A, et al. Differential myocardial gene expression of collagen type I and type III in dilated cardiomyopathy: Effects of myocardial inflammation. Cardiovasc Res 1998; 37: 123-9.
4. Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999; 99: 2750-6.
5. Wilson EM, Spinale FG. Myocardial remodelling and matrix metalloproteinases in heart failure: Turmoil within the interstitium. Ann Med 2001; 33: 623-34.
6. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30.
7. Woessner JF Jr, Nagase H. Introduction to the matrix metalloproteinases (MMPs). In: Matrix Metalloproteinases and TIMPs. New York, Oxford University Press, 2000: 1-10.
8. Kühl U, Noutsias M, Seeberg B, Schultheiss H-P. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75: 295-300.
9. Noutsias M, Seeberg B, Schultheiss HP, Kühl U. Expression of cell adhesion molecules in dilated cardiomyopathy: Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-31.
10. Eghbali M. Cardiac fibroblasts: Function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 1992; 87(suppl 2): 183-9.
11. Prockop DJ, Kivirikko KI. Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403-34.
12. Czaja MJ, Weiner FR, Eghbali M, Giambrone MA, Eghbali M, Zern MA. Differential effects of gamma-interferon on collagen and fibronectin gene expression. J Biol Chem 1987; 262: 13348-51.
13. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86: 1259-65.
14. Simm A, Nestler M, Hoppe V. Mitogenic effect of PDGF-AA on cardiac fibroblasts. Basic Res Cardiol 1998; 93(suppl 3): 40-3.
15. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991; 69: 483-90.
16. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1receptors. J Renin Angiotensin Aldosterone Syst 2001; 2: 117-22.
17. Neumann S, Huse K, Semrau R, et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002; 39: 756-60.
18. Lee AA, Delhaas T, McCulloch AD, Villarreal FJ. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns. J Mol Cell Cardiol 1999; 31: 1833-43.
19. Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Academic Press, 1998: 1-14.
20. Woessner JF Jr, Nagase H. Activation of the zymogen forms of MMPs. In: Matrix Metalloproteinases and TIMPs. New York, Oxford University Press, 2000: 72-86.
21. Miyamori H, Takino T, Seiki M, Sato H. Human membrane type-2 matrix metalloproteinase is defective in cell-associated activation of progelatinase A. Biochem Biophys Res Commun 2000; 267: 796-800.
22. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207-11.
23. Kajita M, Kinoh H, Ito N, et al. Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: Isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Lett 1999; 457: 353-6.
24. Llano E, Pendas AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res 1999; 59: 2570-6.
25. Shimada T, Nakamura H, Ohuchi E, et al. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. Eur J Biochem 1999; 262: 907-14.
26. Velasco G, Cal S, Merlos-Suarez A, et al. Human MT 6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000; 60: 877-82.
27. He CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-6.
28. Murphy G, Allan JA, Willenbrock F, et al. The role of the Cterminal domain in collagenase and stromelysin specificity. J Biol Chem 1992; 267: 9612-8.
29. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: Why the 'hemopexin' domain? Matrix Biol 1997; 15: 511-8.
30. Okada Y, Gonoji Y, Naka K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992; 267: 21712-9.
31. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis. J Clin Invest 1998; 101: 1478-87.
32. Edwards DR, Beaudry PP, Laing TD, et al. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int J Obes Relat Metab Disord 1996; 1996: 20(suppl 3): S9-S15.
33. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375-80.
34. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999; 42: 162-72.
35. Woessner JF Jr, Nagase H. Functions of the TIMPs. In: Matrix Metalloproteinases and TIMPs. New York, Oxford University Press, 2000: 130-5.
36. Gomis-Ruth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997; 389: 77-81.
37. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-9.
38. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728-34.
39. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002; 105: 1983-8.
40. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function. Circ Res 1999; 85: 364-76.
41. Li YY. Kadokami T, Wang P, McTiernan CF, Feldman AM. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002; 282: H983-9.
42. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. Anti tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001; 104: 1094-7.
43. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996; 148: 1639-48.
44. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with endstage dilated cardiomyopathy. Circulation 1998; 97: 1708-15.
45. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214-24.
46. Li J, Schwimmbeck PL, Tschope C, et al. Collagen degradation in a murine myocarditis model: Relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002 (in press).
47. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001; 104: 826-31.
48. Saed GM, Zhang W, Diamond MP. Effect of hypoxia on stimulatory effect of TGF-beta 1 on MMP-2 and MMP-9 activities in mouse fibroblasts. J Soc Gynecol Investig 2000; 7: 348-54.